3r3-31.  
 
Patients with Parkinson's disease develop neurological dysfunction because they lose a particular type of brain cells called dopaminergic neurons. Different ways of treating this disease have been studied for decades, but nothing has been particularly successful in slowing its development. As a result, there was a great need for a new way of dealing with Parkinson's disease, including through stem cells.
 
 
One of the most interesting techniques would be the use of induced pluripotent stem cells (iPSC) or embryonic stem cells (ESC) in order to grow neurons or their predecessors, which would then be transplanted into the brain of patients. Products based on iPSC can potentially be autologous - taken from a patient and not requiring immunosuppression, and ESC products are likely to require immunosuppression, but may have other benefits.
 
was officially launched. Back in July, we now know that the first patient was treated in October. From the publication Siranoski:
 
“In October, neurosurgeon Takayuki Kikuchi, at Kyoto University Hospital, implanted 2.4 million progenitor cells of dopaminergic neurons in a patient’s 50-year-old brain. In the three-hour procedure, the Kikuchi group introduced cells into 12 sites that were centers of dopamine activity. The cells of the dopaminergic neuron progenitor have been shown. improves the symptoms of Parkinson’s disease in monkeys 3–3r365. . ”
 
In the test using allogeneic donor cells.
 
 
Other teams include Joan Loring at Scripps, which focuses on autologous methods, 3r-356. based on iPSC , Lorenz Shteder, who focuses on using approaches, 3r3358. based on ESC
, 3r360. Roger Barker
from Cambridge and Malin Parmar at the University of Lund. The international collaborative group is called GForce-PD . 3r373.
3r373.